Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Meher BenAbdelghani"'
Autor:
Martin Demarchi, Pierre Coliat, Philippe Barthelemy, Roland Schott, Meher BenAbdelghani, Michael Kim, Jocelyn Chung Shii Hii, Peggy Feyaerts, Felicia Rui Xia Ang, Marie Paule Derde, Filip Deforce, Thierry Petit, Chris Schwabe, Chris Wynne, Lisa Soyeon Park, Xavier Pivot
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0248222 (2021)
PurposeThis first-in-human study was designed to evaluate the pharmacokinetic (PK) equivalence between HD204 and the European Union (EU)-sourced bevacizumab, between HD204 and the United States of America (US)-sourced bevacizumab, and between EU-sour
Externí odkaz:
https://doaj.org/article/45bef64f51cc46f89c05d51ff1082315
Autor:
Julien Edeline, Satoshi Hirano, Aurélie Bertaut, Masaru Konishi, Meher Benabdelghani, Katsuhiko Uesaka, Jérôme Watelet, Masayuki Ohtsuka, Pascal Hammel, Yuji Kaneoka, Jean-Paul Joly, Masakazu Yamamoto, Laure Monard, Yoshiyasu Ambo, Christophe Louvet, Masahiko Ando, David Malka, Masato Nagino, Jean-Marc Phelip, Tomoki Ebata
Publikováno v:
European Journal of Cancer. 164:80-87
Although gemcitabine-based chemotherapy is the standard of care for advanced biliary tract cancers (BTCs), adjuvant phase III studies (BCAT in Japan, PRODIGE 12 in France) failed to show benefit, possibly owing to fewer patients (n = 225 and n = 194)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe72cc64c5070de82c9bdbf98444288a
https://doi.org/10.1016/j.ejca.2022.01.009
https://doi.org/10.1016/j.ejca.2022.01.009
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.